Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer

• Verfasst von: Hadaschik, Boris [VerfasserIn]
• Verfasst von: Su, Yun [VerfasserIn]
• Verfasst von: Hüter, Eva [VerfasserIn]
• Verfasst von: Ge, Yingzi [VerfasserIn]
• Verfasst von: Hohenfellner, Markus [VerfasserIn]
• Verfasst von: Beckhove, Philipp [VerfasserIn]
• Titel: Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer
• Verf.angabe: Boris Hadaschik, Yun Su, Eva Huter, Yingzi Ge, Markus Hohenfellner and Philipp Beckhove
• E-Jahr: 2012
• Jahr: April 2012
• Umfang: 8 S.
• Teil: volume:187
• Teil: year:2012
• Teil: number:4
• Teil: pages:1458-1465
• Teil: extent:8
• Fussnoten: Available online 16 February 2012 ; Gesehen am 12.10.2018
• Titel Quelle: Enthalten in: The journal of urology
• Ort Quelle: New York, NY [u.a.] : Elsevier, 1917
• Jahr Quelle: 2012
• Band/Heft Quelle: 187(2012), 4, Seite 1458-1465
• ISSN Quelle: 1527-3792
• DOI: doi:10.1016/j.juro.2011.11.083
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: antigens
• Sach-SW: immunotherapy
• Sach-SW: prostate
• Sach-SW: prostatic neoplasms
• Sach-SW: T-lymphocytes, regulatory
• K10plus-PPN: 1581854188

Abstract

Purpose - Immunotherapy is a promising approach in an effort to control castration resistant prostate cancer. We characterized tumor antigen reactive T cells in patients with prostate cancer and analyzed the suppression of antitumor responses by regulatory T cells. - Materials and Methods - Peripheral blood samples were collected from 57 patients with histologically confirmed prostate cancer, 8 patients with benign prostatic hyperplasia and 16 healthy donors. Peripheral blood mononuclear cells were isolated and antigen specific interferon-γ secretion of isolated T cells was analyzed by enzyme-linked immunospot assay. T cells were functionally characterized and T-cell responses before and after regulatory T-cell depletion were compared. As test tumor antigens, a panel of 11 long synthetic peptides derived from a total of 8 tumor antigens was used, including prostate specific antigen and prostatic acid phosphatase. - Results - In patients with prostate cancer we noted a 74.5% effector T-cell response rate compared with only 25% in patients with benign prostatic hyperplasia and 31% in healthy donors. In most patients 2 or 3 tumor antigens were recognized. Comparing various disease stages there was a clear increase in the immune response against prostate specific antigens from intermediate to high risk tumors and castration resistant disease. Regulatory T-cell depletion led to a significant boost in effector T-cell responses against prostate specific antigen and prostatic acid phosphatase. - Conclusions - Tumor specific effector T cells were detected in most patients with prostate cancer, especially those with castration resistant prostate cancer. Since effector T-cell responses against prostate specific antigens strongly increased after regulatory T-cell depletion, our results indicate that immunotherapy efficacy could be enhanced by decreasing regulatory T cells.